We have compared rapacuronium 2.5 mg kg" 1 (n=20) with succinylcholine 1.5 mg kg" 1 (n=22) in a multicentre, blinded, randomized study in full-term parturients undergoing elective Caesarean section under general anaesthesia. Thiopental 5 mg kg" 1 was given i.v. followed by the neuromuscular blocking agent. Sixty seconds later intubation was performed. Intubating conditions, evaluated as excellent, good or poor, were good to excellent in 95% and 91% in the intent-to-treat patients after rapacuronium and succinylcholine, respectively (ns). Mean onset times at the adductor pollicis muscle for rapacuronium and succinylcholine were 80.4 (SEM 14.4) s and 63.9 (5.6) s (ns) while maximum block was 96 (1.9)% and 99 (0.4)%, respectively (ns). Rate of recovery was significantly longer after rapacuronium; times for return of Tl to 25% were 16.9 (1.5) min and 9.6 (I.I) min for rapacuronium and succinylcholine, respectively (P=0.0004). Maternal side effects included more tachycardia and skin erythema with rapacuronium; no maternal mortality or morbidity, including bronchospasm, occurred in either group. There were no neonatal adverse effects in either group based on: Apgar scores at I and 5 min; times to sustained respiration; neuroadaptive capacity scores at 15 min, 2 h and 24 h; and umbilical venous and arterial blood-gas values and acid-base status. At delivery (17.7 (3.2) min), mean maternal plasma concentrations of rapacuronium were 9041.4 (1259.1) ng ml" 1 and 506.4 (24.9) ng ml" 1 for Org 9488 (the main metabolite). Corresponding values for umbilical venous plasma were 808.0 (92.1) ng ml" 1 and 59.1 (6.5) ng ml" 1 , and for umbilical arterial plasma, 361.4 (56.4) ng ml" 1 and 29.7 (4.6) ng ml" 1 , respectively. Umbilical venous to maternal venous ratios for rapacuronium and Org 9488 were 8.8% (1.3)% and 10.2 (1.7)%, respectively. 1999; 83:862-7 Keywords: neuromuscular block, rapacuronium; neuromuscular block, succinylcholine; anaesthesia, obstetrics; anaesthetic techniques, induction Accepted for publication : July 13, 1999 Succinylcholine is the neuromuscular blocking drug of but with a long duration of effect. 3 There is a need for a choice for rapid sequence induction because of its fast onset non-depolarizing neuromuscular blocking drug with a rapid and short duration of action. However, it is a depolarizing onset of action comparable with succinylcholine and that agent with many undesirable side effects, such as cardiac can be antagonized while its neuromuscular blocking effect arrhythmia, increase in intraocular or intragastric pressure, is still profound (e.g. with unsuccessful intubation), muscle fasciculations and postoperative muscle pain. 1 2 Rapacuronium, the 16-N-allyl-17-P-proprionate analogue Moreover, succinylcholine is contraindicated in patients of vecuronium, is a new aminosteroid non-depolarizing with hyperkalaemia or a family history of malignant hyper-neuromuscular blocking drug 4 " 6 with an ED 90 of thermia. A non-depolarizing neuromuscular blocking drug 1.15 mg kg" 1 . 5 At a dose of 1.5 mg kg" 1
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British Journal of Anaesthesia an intermediate duration of action (about 24 min) which can be shortened to 12 min by administration of neostigmine 10 [ig kg" 1 , 2 min after injection. 4 Routes of elimination of rapacuronium are still undetermined in humans but are unrelated to plasma cholinesterase. The drug is partially converted into a 3-OH metabolite, Org 9488, which is a more potent neuromuscular blocking agent than rapacuronium (ED 90 0.5 mg kg" 1 ) and has a longer duration of action (54 min for 75% recovery of single twitch). 9 Determination of Org 9488 concentrations in maternal and fetal plasma is therefore important.
In this study, we have compared the neuromuscular blocking properties of rapacuronium and succinylcholine, maternal and neonatal safety of rapacuronium in lowrisk obstetrics and the degree of placental transfer of rapacuronium and its metabolite Org 9488.
Patients and methods
Between February 1996 and May 1997, we performed an assessor-blinded, randomized, multicentre study at the University of Texas, University of Southern California, LA, University of Miami, and Robert Wood Johnson Medical School, NJ. After obtaining approval from the Institutional Review Board of each centre, the research office of Organon Inc. at New Jersey randomized, supplied and dispatched the drugs to the pharmacy department of the corresponding centre. The dose was subsequently delivered to the anaesthetist who was blinded to the nature of the injectate. We studied parturients aged 18-45 yr, with a gestational age 5=36 weeks, carrying a normal fetus with cephalic presentation, after obtaining written, informed consent. Subjects were healthy parturients with Mallampati class I or II airway. 10 They did not have any illnesses and were not receiving drugs that might alter their response to the neuromuscular blocking drug or jeopardize their safety.
Patients were undergoing elective Caesarean section under general anaesthesia. Premedication, as preferred by the treating anaesthetist, comprised metoclopramide 10 mg i.v. and/or an oral antacid in the form of sodium bicitrate 30 ml or sodium bicarbonate 10 ml. Before induction of anaesthesia, the uterus was displaced to the left and monitors were applied, including ECG and non-invasive electronic arterial pressure. Neuromuscular function was monitored electromyographically using a Relaxograph (Datex, Helsinki, Finland). Using surface electrodes and a train-offour (TOF) pattern of stimulation, supramaximal square wave stimuli of 0.2 ms at 2 Hz every 10 s were delivered to the ulnar nerve at the wrist of the opposite arm from the i.v. infusion. The electromyographic (EMG) response of the adductor pollicis muscle was then recorded. Onset time was defined as the time between completion of injection and maximum block at the adductor pollicis muscle. No precurarizing drug or lidocaine i.v. was used.
After preoxygenation for 3 min, thiopental 5 mg kg" 1 was given into a rapidly flowing i.v. infusion and cricoid (Table 1) . Anaesthesia was maintained with 0.5-0.75% isoflurane (end-tidal) and 50-60% nitrous oxide in oxygen. After delivery, the concentration of isoflurane was reduced to 0.5% and incremental doses of an opioid or a benzodiazepine, or both, were administered, as indicated clinically. When required at the end of surgery, increments of glycopyrrolate 0.2 mg and neostigmine 1 mg (maximum total dose of neostigmine 3.5 mg) were given i.v to antagonize residual neuromuscular block. Extubation was performed after clinical recovery (head lift, hand squeeze, tongue extension) and TOF recovery to 3=90% of baseline. From the continuous EMG tracings, times to return of Tl to 25% in both groups and T4/Tl=70% in the rapacuronium group were calculated.
Clinical signs that may be related to histamine release (e.g. anaphylactic reactions, bronchospasm or erythema) were recorded. Heart rate and indirect arterial pressure measurements were observed before and after injection of the neuromuscular blocking drugs, at 1-min intervals for 10 min.
The newborn was evaluated by 1-and 5-min Apgar scores, time to sustained respiration, neuroadaptive capacity score (NACS at 15 min, 2 h and 24 h), and umbilical arterial and venous blood-gas values and acid-base status. Twenty-four hours after delivery, the postoperative condition of the mother and newborn were assessed.
Maternal blood samples before drug administration and at the time of delivery were obtained to measure placental transfer of rapacuronium and its metabolite, Org 9488. Also at delivery, umbilical arterial and venous plasma concentrations were obtained for measurement of rapacuronium and Org 9488 concentrations. Umbilical venous to Table 2 Non-compliance with the study. In (a), all efficacy data were excluded. In (b), only intubation scores were excluded. No impact on efficacy assessment Plasma samples were assayed for rapacuronium and Org 9488 using high-pressure liquid chromatography (HPLC) with mass selective detection. Rapacuronium, Org 9488 and an internal standard d 10 -rapacuronium were extracted from 500 |iil of acidified human plasma into dichloroethane. Dichloroethane was evaporated under nitrogen and the residue was reconstituted in 250 |il of (85/15) ammonium acetate 10 mmol litre" 1 in 1% acetic acid-acetonitrite. Separation was achieved on an Asaphipak column with a mobile phase composed of (75/25) ammonium acetate 10 mmol litre" 1 in 1% acetic acid-acetonitrite. Detection was by single ion reaction monitoring of the ions 597.7, 555.7 and 607.7 for rapacuronium, Org 9488 and the internal standard, respectively. The lower limit of quantification was set at 2.00 ng ml" 1 for both rapacuronium and Org 9488. Inter-day variability for rapacuronium and Org 9488 did not exceed 6.6% and 12.8%, respectively.
Subjects were grouped as follows: the all-subject randomized group comprised all those admitted to the study and randomized; and the intent-to-treat group comprised all subjects treated. Patients in the latter group were allocated to one of the following subgroups: (a) per-protocol group-no study violations; (b) major study violationthose who received a dose of neuromuscular blocking drug different from specified by ±10% or non-compliance with exclusion criteria; (c) minor study violation-when the dose of thiopental differed by ± 10% of the study dose; (d) study deviation-when isoflurane was used in a concentration higher than 0.75% or another anaesthetic was used for maintenance (Table 2) .
Data are presented as mean (SEM) and were analysed using one-way analysis of variance with treatment as a factor. In addition, the Cochran-Mantel-Haenszel test 12 was applied when necessary. P<0.05 was considered significant.
Results
The all-subject randomized group comprised 43 parturients from four centres. One patient in the rapacuronium group was excluded before drug administration as surgery was cancelled by the obstetrician. Thus the intent-to-treat group comprised 42 parturients of whom 20 received rapacuronium* and 22 succinylcholine. Five patients had major study violations, three in the rapacuronium group and two in the succinylcholine group; three had minor violations, two in the rapacuronium group and one in the succinylcholine group (Table 2) . With the exception of patient height, there was no significant difference between the two groups in patient characteristics or surgically related data (Table 3) .
Efficacy-
Efficacy was evaluated by comparing intubating conditions at 60 s and the rate of recovery. Intubating conditions at 60 s are presented in Table 4 for the intent-to-treat and per-protocol groups (after exclusion of those with study violations). Intubating scores were similar for rapacuronium and succinylcholine. In the intent-to-treat group, rapacuronium 2.5 mg kg" 1 provided excellent to good conditions in 95% of patients and succinylcholine 1.5 mg kg" 1 in 91%. In the per-protocol group, rapacuronium produced excellent to good conditions in 93% of patients and succinylcholine in 89%. No patient required additional neuromuscular blocking drug for intubation. Mean onset times at the adductor pollicis muscle for rapacuronium and succinyl- Table 4 Intubation score at 60 s in the intent-to-treat and per-protocol groups (number (%)). No significant difference between groups (P=0.882) choline were 80.4 (14.4) s and 63.9 (5.6) s, respectively (ns); maximum block was 96 (1.9)% and 99 (0.4)%, respectively (ns) ( Table 5 ). Time to recovery of Tl to 25% was longer in the rapacuronium than in the succinylcholine group with mean times of 16.9 (1.5) min and 9.6 (1.1), respectively (P=0.0004). During surgery, only two subjects in the rapacuronium group received supplementary nondepolarizing neuromuscular blocking drug (vecuronium) while 15 in the succinylcholine group received additional doses of neuromuscular blocking drugs (eight vecuronium, three mivacurium. three rocuronium and one succinylcholine). All but one subject (n=19) in the rapacuronium group and 11 in the succinylcholine group received neostigmine. Otherwise, clinical recovery was similar in both groups.
Intubation score

Excellent
Time to recovery of T4/T1 =70% for rapacuronium was not measurable. Two patients received vecuronium before T4/T1 reached 70% and 17 patients received neostigmine.
Cardiovascular effects
During the 10-min period after administration of the neuromuscular blocking drug, there was a significant increase in heart rate in both groups (Fig. 1) . The peak increases in heart rate after rapacuronium and succinylcholine were 48% and 19%, respectively. These increases were 25% and 6% above baseline at 10 min after drug administration. Statistically, the percentage increase in heart rate in the rapacuronium group was significantly higher than that in the succinylcholine group at each time during the 10-min period (P<0.05). For mean arterial pressure, the effect was biphasic; it increased initially above baseline and then decreased (Fig. 2) . During the first 7 min, mean arterial pressure was significantly higher in the succinylcholine group than in the rapacuronium group (P<0.05).
Histamine release
Histamine-related events such as skin erythema occurred in significantly more patients in the rapacuronium (20%) than in the succinylcholine (5%) group (P<0.05). However, no bronchospasm was detected in any patient. No maternal mortality or life-threatening complications occurred in either group.
Newborn
Assessment of the newborn was similar in both groups. Apgar score at 1 min was less than 7 in four newborns in each group (Table 6) . By 5 min, all but one in each group had a score of 7 or more. Both of the neonates with low Apgar scores at 5 min had respiratory distress syndrome. Time to sustained respiration, NACS, arterial blood-gas values and acid-base status were normal in both groups (Table 6 ).
Serum concentrations of rapacuronium and Org 9488 (main metabolite)
Maternal and umbilical serum concentrations are shown in Table 7 . At delivery, umbilical venous (UV) to maternal venous (MV) percentages for rapacuronium and Org 9488 were 8.8 (1.3)% and 10.2 (1.7)%, respectively. There was no correlation between UV/MV percentage and neuromuscular blocking drug-delivery time. There was also no correlation between fetal drug concentrations and NACS at 15 min, 2 h or 24 h.
Discussion
We have found that intubating conditions in parturients after rapacuronium 2.5 mg kg" 1 were good to excellent in more than 90% of patients and were comparable with those of succinylcholine 1.5 mg kg" 1 . We also found that rapacuronium was safe. These findings confirm the results in general surgical patients. 4 5 13 Rapacuronium has the shortest onset of action of any non-depolarizing drug. 7 14 Its rapid onset of action is a result mainly of its low potency. 4 Thus a large number of molecules are administered, producing a large initial gradient between the plasma and site of action (law of mass action). Moreover, the profound lipophilicity of rapacuronium promotes more rapid diffusion through membranes than other non-depolarizing agents, resulting in more rapid equilibration between plasma and the effect compartment. Onset time at the adductor pollicis muscle in this study (80.4 (14.1) s) was comparable with that found by other investigators. 4 5 7 15 Intubating conditions at 60 s were excellent with rapacuronium as paralysis at the laryngeal adductor muscles occurred earlier than that at the adductor pollicis muscle (52 (14) s vs 82 (21) s). 15 It may be possible to antagonize the profound block produced by rapacuronium by neostigmine. 4 Initial studies showed that administration of neostigmine 40 (_ig kg"" 1 with methyl-atropine 7 [Xg kg" 1 , 2 min after injection of rapacuronium 1.5 mg kg" 1 , significantly shortened recovery time from 24.1 to 11.6 min. 4 In contrast, antagonism of an intense pancuronium-, vecuronium-or atracurium-induced neuromuscular block did not result in sufficient clinical recovery to allow adequate ventilation. 16 In this respect, rapacuronium has a desirable feature which may be of use during difficult intubation. However, these findings have not been confirmed. Moreover, the dose used in our study (2.5 mg kg" 1 ) was greater than that used by Wierda and colleagues (1.5 mg kg" 1 ). 4 Despite a higher incidence of erythema after administration of rapacuronium, we did not encounter any serious histamine-related effects such as bronchospasm or anaphylactic reaction.
In our study, compared with succinylcholine, rapacuronium produced more marked tachycardia and less of an increase in arterial pressure in the first 10 min after administration. However, these cardiovascular changes were not clinically significant and did not require treatment. In non-obstetric patients, rapacuronium has also been reported to cause significant tachycardia which was dose-related, 4 13 14 n a i m ough other investigators found no significant" change. 818 The cause of tachycardia could be block of the parasympathetic nerve supply to the heart, stimulation of the sympathetic nervous system, release of histamine or a compensatory reaction to vasodilatation. The exact mechanism awaits further investigation. In surgical patients, the effects on arterial pressure also differed between studies. Although Bikhazi and colleagues 18 and Lichtor and colleagues 8 found no changes, others 4 7 1 7 found drug-induced hypotension which was attributed to vasodilatation. In our study, caution is required in explaining the initial hypertension because of the associated sympathetic stimulation caused by laryngoscopy, intubation and surgical incision. In this and other studies, no arrhythmias were noted after rapacuronium.
We found no adverse effects in the neonate. This was supported by the fact that the percentage of drug crossing the placenta to the fetus was lower than any other nondepolarizing drug. UV/MV percentages for pancuronium, vecuronium and rocuronium are 26%, 11% and 16%, respectively 31920 while that of rapacuronium is 8.8%. There was no correlation between umbilical venous plasma drug concentrations and NACS. In summary, rapacuronium 2.5 mg kg * in parturients had a similar onset time and provided the same excellent to good intubating conditions as succinylcholine 1.5 mg kg" 1 . We found no serious or life-threatening side effects after rapacuronium although the number of patients studied was small. Placental transfer of drug was the lowest of any non-depolarizing neuromuscular blocking drug available. Rapacuronium had no adverse effects in the neonate. When the use of succinylcholine is contraindicated or inadvisable and a non-depolarizing neuromuscular blocking drug is needed, rapacuronium may be the drug of choice in elective Caesarean section.
